Physician profile
Sofia Amoashiy
NPI 1801906110
$4,716.97
in general payments reported to CMS, 2019-2025
35 companies · $515 in 2025
The $515 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $506 · 2020: $494 · 2021: $752 · 2022: $1,009 · 2023: $554 · 2024: $887 · 2025: $515.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,845 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,844.83 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $801.79 | 2019-2025 | Austedo, Ajovy, Austedo Xr |
| Mdd US Operations, LLC | $589.90 | 2019-2025 | Gocovri, Gocovri |
| Abbvie INC. | $468.98 | 2023-2025 | Qulipta, Botox, Ubrelvy |
| Neurocrine Biosciences, INC. | $392.47 | 2019-2024 | Ingrezza |
| Janssen Pharmaceuticals, INC | $297.79 | 2021-2022 | |
| Ucb, INC. | $278.79 | 2019-2021 | |
| Lilly USA, LLC | $210.59 | 2020-2025 | Kisunla, Amyvid |
| Vanda Pharmaceuticals INC. | $179.34 | 2022-2025 | Fanapt, Hetlioz |
| Avanir Pharmaceuticals, INC. | $158.00 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $144.92 | 2019-2021 | |
| Celgene Corporation | $133.46 | 2022-2024 | Zeposia |
| Sunovion Pharmaceuticals INC. | $126.24 | 2019 | |
| Emd Serono, INC. | $118.26 | 2022-2024 | Mavenclad |
| Idorsia Pharmaceuticals US INC | $112.78 | 2023 | Quviviq |
| Otsuka America Pharmaceutical, INC. | $108.38 | 2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $82.72 | 2020-2025 | Cobenfy |
| Biogen, INC. | $57.15 | 2021-2022 | |
| Bausch Health US, LLC | $49.61 | 2020 | |
| Sk Life Science, INC. | $46.03 | 2020 | |
| Eisai INC. | $42.86 | 2024 | |
| Avion Pharmaceuticals | $40.58 | 2023 | Dhivy |
| Supernus Pharmaceuticals, INC. | $29.96 | 2019 | |
| Grt US Holding, INC. | $29.77 | 2022 | |
| Impel Pharmaceuticals INC. | $23.07 | 2023 | Trudhesa |
| Alnylam Pharmaceuticals INC. | $23.00 | 2021 | |
| Adamas Pharmaceuticals, INC. | $21.97 | 2020 | |
| Lundbeck LLC | $21.47 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $18.08 | 2022 | |
| Genzyme Corporation | $18.06 | 2021 | |
| Acadia Pharmaceuticals INC | $17.46 | 2021 | |
| Currax Pharmaceuticals LLC | $17.43 | 2021 | |
| Amneal Pharmaceuticals LLC | $14.43 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $14.26 | 2020 | |
| Boston Scientific Corporation | $14.26 | 2019 | |
| Promius Pharma LLC | $13.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sofia Amoashiy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.